Previous Close | 30.30 |
Open | 32.64 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 31.21 - 32.64 |
52 Week Range | 23.45 - 37.91 |
Volume | |
Avg. Volume | 21,530 |
Market Cap | 61.86B |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | 46.84 |
EPS (TTM) | 0.68 |
Earnings Date | N/A |
Forward Dividend & Yield | 0.39 (1.28%) |
Ex-Dividend Date | Sept 27, 2024 |
1y Target Est | 36.01 |
AstraZeneca CEO Pascal Soriot joined Yahoo Finance to discuss the company's earnings today.
Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.
Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.